So far, researchers have identified over 300 angiogenesis inhibitors. There are about 21 that are endogenous, found in the body. The rest of the inhibitors are compounds that have been developed which have specific mechanisms allowing precise application.Some of the inhibitors target angiogenic growth factors or their receptors. Others target intracellular signaling, and still others block endothelial cell proliferation.There are currently approximately 40 angiogenic inhibitors in clinical trials sponsored by the National Cancer Institute, medical centers and universities, and biotechnology and pharmaceutical companies. It is expected it may take 2-3 years before drugs are approved and available to the general population.
Currently, the following drugs have been shown to be to have anti-angiogenic properties.
Thalidomide now prescribed for leprosy and available off-label is currently being used in clinical trials as a blocker of angiogenic growth factors (bFGF, VEGF, TNF-alpha).
Celebrex and Vioxx, currently prescribed for arthritis, have both been shown to have anti-angiogenic properties. Celebrex has received approval for adjunctive treatment of familial adenomatous polyposis (colorectal polyps) which may be a precursor to cancer. These drugs are in a class of drugs that inhibit COX-2, a protein implicated in the formation of tumors.
Captopril (a high blood pressure medication) also has anti-angiogenic properties.
Click on links below to learn more.
This page from the Ovarian Research Cancer Notebook provides a listing of Angiogenesis inhibitors. At this site, be sure to click also on the Anti-Angiogenesis Overview heading.
“Angiogenesis and Cancer Control: From Concept to Therapeutic Trial”
This is a research paper published in 1999, authored by Steven Brem, M.D., of the H. Lee Moffitt Cancer Center & Research Institute. Table 2 lists both stimulators and inhibitors by category. Tables 3-8 list by category, inhibitors currently in clinical trials.
“Inhibition of Angiogenesis”
This is from the Special Project Angiogenesis site provided by the University of Brescia in Italy. This page is a discussion and listing of Angiogenesis inhibitors.
“Angiogenesis Inhibitors in Cancer Research”
This a listing of current cancer trials from the National Cancer Institute and the National Institute of Health.